EPS for Bavarian Nordic A/S (BVNRY) Expected At $-0.25

May 17, 2018 - By Larry Park

Bavarian Nordic A/S (OTCMKTS:BVNRY) Logo

Analysts expect Bavarian Nordic A/S (OTCMKTS:BVNRY) to report $-0.25 EPS on May, 24 before the open.They anticipate $0.24 EPS change or 2,400.00 % from last quarter’s $-0.01 EPS. After having $-0.31 EPS previously, Bavarian Nordic A/S’s analysts see -19.35 % EPS growth. It closed at $9.91 lastly. It is down 0.00% since May 17, 2017 and is . It has underperformed by 11.55% the S&P500.

Bavarian Nordic A/S, a biotechnology company, develops, makes, and commercializes a portfolio of novel vaccines for the prevention and treatment of life-threatening infectious diseases and cancer. The company has market cap of $960.01 million. The firm markets non-replicating smallpox vaccine under the IMVAMUN and IMVANE names. It has a 31.66 P/E ratio. It is also developing MVA-BN Filo that is in Phase III trial for the treatment of Ebola and Marburg; MVA-BN RSV, which is in Phase II clinical development stage for the prevention of respiratory syncytial virus; and MVA-BN HPV that is in preclinical development stage to treat human papillomavirus.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.